Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis.
Authors:
- D A CollinsDCD A Collins
- R P JazrawiRJR P Jazrawi
- P A JacksonPJP A Jackson
- C M CorbishleyCCC M Corbishley
- B E BourkeBBB E Bourke
- T C NorthfieldTNT C Northfield
Open Access
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter (H pylori) are both associated with an increased risk of peptic ulceration and gastropathy. It is not known, however, if there is an interaction between these two agents, and thus whether or not screening for H pylori before NSAID treatment is of value. The aim of this study was to find out if H pylori potentiates the damaging effects of NSAIDs. Fifty two patients with rheumatoid arthritis requiring longterm NSAID treatment were studied. Dyspeptic symptoms were assessed according to a standardised questionnaire. Gastroscopy was performed after a one week washout period during which NSAIDs were discontinued. Gastric and duodenal mucosal damage was graded endoscopically. H pylori was identified by biopsy urease test and by histological tests. Investigations were repeated after one month's treatment with an NSAID. Patients with H pylori infection (n = 26) had a higher dyspeptic symptom score (p < 0.05). One patient with duodenal ulcer (H pylori +ve) and two with endoscopic gastritis (both H pylori +ve) were excluded from further study. Forty two subjects completed the study. After treatment there was a rise in the gastric damage score both in the H pylori +ve (p = 0.06) and the H pylori -ve (p < 0.005) groups. There was no difference in the extent of increase in grade or the final grade at the end of the treatment period between the H pylori +ve and -ve patients. It is concluded that H pylori infection is associated with increased dyspeptic symptoms in patients receiving NSAIDs but that it does not potentiate NSAID gastropathy.Keywords
This publication has 30 references indexed in Scilit:
- SEROLOGICAL EVIDENCE OF INFECTION WITH HELICOBACTER PYLORI MAY PREDICT GASTROINTESTINAL INTOLERANCE TO NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TREATMENT IN RHEUMATOID ARTHRITISRheumatology, 1991
- Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1990
- Campylobacter pylori infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error.Journal of Clinical Pathology, 1989
- Rapid urease test provides specific identification of Campylobacter pylori in antral mucosal biopsiesPostgraduate Medical Journal, 1988
- Peptic ulcer in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1988
- NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED DYSPEPSIA IS CAMPYLOBACTER PYLORIDIS IMPLICATED?Rheumatology, 1988
- Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.Journal of Clinical Pathology, 1988
- Gastric adaptation occurs with aspirin administration in manDigestive Diseases and Sciences, 1983
- Endoscopic Evaluation of the Effects of Aspirin, Buffered Aspirin, and Enteric-Coated Aspirin on Gastric and Duodenal MucosaNew England Journal of Medicine, 1980
- Acute gastric mucosal injury during continuous or interrupted aspirin ingestion in humansDigestive Diseases and Sciences, 1976